Conatus Pharmaceuticals (CNAT), a clinical stage biotech, announces that it has initiated a Phase 2 clinical trial for its lead product, emricasan, a novel treatment for patients with nonalcoholic fatty liver disease (NAFLD).
The study will enroll 40 patients at four US sites. The primary endpoint is a reduction of elevated levels of key biomarkers implicated in the disease.
The company expects top-line results in the second half of this year.
Conatus shares currently trade at $11, up 15% from its July 26 opening day close of $9.60.
74 mutual funds are owners.